Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression

Androgen ablation therapy represents the first line of therapeutic intervention in men with advanced or recurrent prostate tumors. However, the incomplete efficacy and lack of durable response to this clinical strategy highlights an urgent need for alternative treatment options to improve patient ou...

Descripción completa

Detalles Bibliográficos
Autores principales: HE, SUQIN, ZHANG, CHAOHUA, SHAFI, AYESHA A., SEQUEIRA, MANUEL, ACQUAVIVA, JAIME, FRIEDLAND, JULIE C., SANG, JIM, SMITH, DONALD L., WEIGEL, NANCY L., WADA, YUMIKO, PROIA, DAVID A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2012
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583620/
https://www.ncbi.nlm.nih.gov/pubmed/23152004
http://dx.doi.org/10.3892/ijo.2012.1698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583620/
https://www.ncbi.nlm.nih.gov/pubmed/23152004
http://dx.doi.org/10.3892/ijo.2012.1698

Ejemplares similares